Synergism of PARP inhibitor and MET inhibitor in multiple cancer types with intrinsic and acquired PARP inhibitor resistances

被引：1

作者：

Chen, Mei-Kuang ^{[1
]}

Xia, Weiya ^{[1
]}

Dong, Qiongzhu ^{[2
]}

Du, Yi ^{[3
]}

Wang, Hung-Ling ^{[4
]}

Tapia, Coya ^{[1
]}

Wei, Yongkun ^{[1
]}

Han, Ye ^{[5
]}

Chu, Yu-Yi ^{[1
]}

Yam, Clinton ^{[1
]}

Gao, Yuan ^{[1
]}

Wang, Yu-Han ^{[1
]}

Meric-Bernstam, Funda ^{[1
]}

Liu, Jinsong ^{[1
]}

Wang, Shao-Chun ^{[4
]}

Yu, Dihua ^{[1
]}

Hung, Mien-Chie ^{[4
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Fudan Univ, Shanghai, Peoples R China

[3] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA

[4] China Med Univ, Taichung, Taiwan

[5] China Med Univ, Affiliated Shengjing Hosp, Shenyang, Peoples R China

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-5682

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5682

引用

页数：2

共 50 条

[41] The role of PARP inhibitor combination therapy in ovarian cancer
Hockings, Helen
Miller, Rowan E.
[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[42] PARP trapping is governed by the PARP inhibitor dissociation rate constant
Gopal, Angelica A.
Fernandez, Bianca
Delano, Justin
Weissleder, Ralph
Dubach, J. Matthew
[J]. CELL CHEMICAL BIOLOGY, 2024, 31 (07)
[43] Diverse mechanisms of PARP inhibitor resistance in ovarian cancer
Wakefield, Matthew John
Nesic, Ksenija
Kondrashova, Olga
Scott, Clare L.
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1872 (02):
[44] A TREND OF THE TREATMENT FOR BREAST CANCER PATIENTS (PARP INHIBITOR)
Tamura, K.
[J]. ANNALS OF ONCOLOGY, 2012, 23 : 76 - 77
[45] Olaparib, PARP1 inhibitor in ovarian cancer
Marchetti, Claudia
Imperiale, Ludovica
Gasparri, Maria Luisa
Palaia, Innocenza
Pignata, Sandro
Boni, Terenzio
Bellati, Filippo
Panici, Pierluigi Benedetti
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1575 - 1584
[46] An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Xu, Jing
Gao, Yi
Luan, Xiaotian
Li, Ke
Wang, Jing
Dai, Yilin
Kang, Mingyi
Lu, Chong
Zhang, Minhua
Lu, Chris X.
Kang, Yu
Xu, Congjian
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (05) : 683 - 695
[47] Action mechanism of talazoparib as a PARP inhibitor for lung cancer
Honda, Noritaka
Myat, Aung B.
Tong, Ying
Onodera, Takae
Umeyama, Yasuhiro
Taniguchi, Hirokazu
Yamaguchi, Hiroyuki
Masutani, Mitsuko
[J]. CANCER SCIENCE, 2023, 114 : 2200 - 2200
[48] Anti-tumor effects in combination with PARP inhibitor and DNMT inhibitor in ovarian cancer
Lee, Jeong-Won
Jeong, Soo Young
Ryu, Ji Yoon
Lee, Yoo-Young
Esun, Paik
[J]. CANCER RESEARCH, 2019, 79 (13)
[49] An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
Jing Xu
Yi Gao
Xiaotian Luan
Ke Li
Jing Wang
Yilin Dai
Mingyi Kang
Chong Lu
Minhua Zhang
Chris X. Lu
Yu Kang
Congjian Xu
[J]. Cancer Chemotherapy and Pharmacology, 2022, 89 : 683 - 695
[50] PARP Inhibitor Radiosensitization of Small Cell Lung Cancer Differs by PARP Trapping Potency
Lok, B.
Laird, J.
Ma, J.
De Stanchina, E.
Poirier, J.
Rudin, C.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S433 - S433

← 1 2 3 4 5 →